2. Search Result
Search Result
Results for "

catalytically active

" in MedChemExpress (MCE) Product Catalog:

62

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

6

Peptides

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-E70017
    Peptidase, microorganism

    Erepsin; Peptidase (IMPa)

    		 Others Others
    Peptidase (IMPa) (Erepsin) is catalytically active enzyme that cleaves peptide bonds in proteins and peptides by hydrolysis .
    Peptidase, microorganism
  • HY-E70021
    UDP-Glc 4-epimerase (GalE)

    		Others Others
    UDP-Glc 4-epimerase (GalE) is catalytically active enzyme. UDP-Glc 4-epimerase (GalE) catalyzes the reversible conversion of abundantly available UDP-glucose to UDP-galactose .
    UDP-Glc 4-epimerase (GalE)
  • HY-E70069
    Endo S2, Streptococcus pyogenes

    		Others Others
    Endo-β-N-acetylglucosaminidase (Endo S2) is a key enzyme involved in the processing of free oligosaccharides in the cytosol. Endo-β-N-acetylglucosaminidase catalyzes hydrolysis of N-linked oligosaccharides .
    Endo S2, Streptococcus pyogenes
  • HY-109143
    Elsubrutinib
    2 Publications Verification

    ABBV-105

    		 Btk Inflammation/Immunology
    Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor. The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease .
    Elsubrutinib
  • HY-115383
    Roflupram
    1 Publications Verification

    		 Phosphodiesterase (PDE) Neurological Disease Inflammation/Immunology
    Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC50 of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors .
    Roflupram
  • HY-153967
    BLU0588
    1 Publications Verification

    		 PKA Cancer
    BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research .
    BLU0588
  • HY-Y0262B
    Sodium oxalate,ACS,99.5%

    Ethanedioic acid sodium,ACS, 99.5%

    		 Biochemical Assay Reagents Mitochondrial Metabolism Metabolic Disease Cancer
    Sodium oxalate is an orally active dispersant and coordination agent. Sodium oxalate causes mitochondrial dysfunction. Sodium oxalate has catalytic enhancing activity. Sodium oxalate induces stable chronic kidney disease. Sodium oxalate induces highly malignant and undifferentiated breast tumors .
    Sodium oxalate,ACS,99.5%
  • HY-157527
    hAChE-IN-7

    		Cholinesterase (ChE) Beta-secretase Neurological Disease
    hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on hAChE (IC50=69.8 nM) and hBuChE (IC50=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC50=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research .
    hAChE-IN-7
  • HY-E70039
    alpha-2-3,6,8-Sialidosidase (SpNanA)

    		Others Others
    alpha-2-3,6,8-Sialidosidase (SpNanA) catalyses hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates .
    alpha-2-3,6,8-Sialidosidase (SpNanA)
  • HY-E70692
    CLK3 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CLK3 is a nuclear dual-specificity kinase has been shown to undergo conserved alternative splicing to generate catalytically active (Clk) and inactive (ClkT) isoforms. CLK3 Recombinant Human Active Protein Kinase is a recombinant CLK3 protein that can be used to study CLK3-related functions .
    CLK3 Recombinant Human Active Protein Kinase
  • HY-E70066
    UDP-sugar pyrophosphorylase (AtUSP)

    		Others Others
    UDP-sugar pyrophosphorylase (AtUSP) is a broad substrate enzyme that synthesizes nucleotide sugars. UDP-sugar pyrophosphorylase catalyzes the conversion of various monosaccharide 1-phosphates to the respective UDP-sugars in the salvage pathway .
    UDP-sugar pyrophosphorylase (AtUSP)
  • HY-171036
    GAPDH-IN-1

    		Endogenous Metabolite Metabolic Disease
    GAPDH-IN-1 (Compound F8) is a GAPDH inhibitor (IC50 of 39.31 μM for GAPDH enzymatic activity). GAPDH-IN-1 forms a covalent adduct with an aspartic acid in the active site to displace NAD +, a cofactor of the enzyme, with concomitant enhancement of the cysteine-reactive probe reaction with the catalytic cysteine .
    GAPDH-IN-1
  • HY-P10808
    RSRGVFF

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    RSRGVFF (FOXP3 inhibitor P60) is a mixed-type angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, boasting an IC50 value of 5.01 μM . RSRGVFF is capable of binding to both active and non-active sites of ACE and its substrate HHL complex, thus reducing the catalytic activity of ACE. RSRGVFF can be further utilized for research on lowering hypertension .
    RSRGVFF
  • HY-150728
    AChE-IN-22

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-22 (compound 10q) is a selective acetylcholinesterase (AChE) inhibitor against AChE and BuChE with the IC50 values of 0.88 μM and 10 μM, respectively. AChE-IN-22 can bind to both the CAS (catalytic active site) and PAS (peripheral anionic site) of AChE and has the potential for the research of Alzheimer's disease .
    AChE-IN-22
  • HY-P11306
    Biotin-(Oaa)3-epoxomicin

    		Proteasome Others
    Biotin-(Oaa)3-epoxomicin (Compound 13) is a biotinylated active form of Epoxomicin (HY-13821). Biotin-(Oaa)3-epoxomicin is a high affinity probe targeting Proteasome. Biotin-(Oaa)3-epoxomicin covalently binds to multiple proteasome catalytic subunits (such as LMP7, Z and MECL1) .
    Biotin-(Oaa)3-epoxomicin
  • HY-10572A
    (R)-Efavirenz

    (R)-DMP 266; (R)-EFV; (R)-L-743726

    		 Reverse Transcriptase Infection
    (R)-Efavirenz ((R)-DMP 266) is a non-nucleoside reverse transcriptase inhibitor that acts by non-competitive inhibition of the viral enzyme. (R)-Efavirenz can be metabolized by CYP2B6 to 8-hydroxyefavirenz in a highly stereoselective manner. (R)-Efavirenz is promising to be a useful probe for the CYP2B6 active site and catalytic mechanisms .
    (R)-Efavirenz
  • HY-P5489
    IGRP(206-214)

    		IFNAR Metabolic Disease Inflammation/Immunology
    IGRP(206-214) is a biological active peptide. IGRP(206-214) corresponds to residues 206-214 of murine islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). IGRP(206-214) is T cells specific for proinsulin and IGRP induces diabetes in non-obese diabetic (NOD) mice .
    IGRP(206-214)
  • HY-W728451
    URB694

    		FAAH Cardiovascular Disease Neurological Disease
    URB694 is a carbamate FAAH inhibitor that irreversibly carbamoylate the nucleophile catalytic serine in FAAH active site. URB694 exhibits antidepressant-like activity and cardioprotective effects. URB694 can be used to prepare 11C-Carbonyl-URB694 for in vivo positron emission tomography (PET) imaging studies of the brain FAAH .
    URB694
  • HY-149484
    AChE/BChE-IN-15

    		Cholinesterase (ChE) Neurological Disease
    AChE/BChE-IN-15 (Compound 6d) is an AChE/BChE inhibitor, with IC50s of 20 nM and 220 nM respectively. AChE/BChE-IN-15 binds to both catalytic anionic site (CAS) and peripheral anionic site (PAS) in the active sites of AChE and BChE. AChE/BChE-IN-15 can be used for research of Alzheimer’s disease .
    AChE/BChE-IN-15
  • HY-125384
    ARN14686

    		Fluorescent Dye Inflammation/Immunology
    ARN14686 is an activity-based protein profiling (ABPP) probe. ARN14686 inhibits hNAAA with high potency (IC50=0.006 μM). ARN14686 interacts with NAAA via covalent binding to the N-terminal cysteine. ARN14686 binds only to the catalytically active form of NAAA, and may serve therefore as an efficient activity-based probe .
    ARN14686
  • HY-158335
    DXR-IN-1

    		Parasite Infection
    DXR-IN-1 (Compound 13E) is an inhibitor of 1-deoxy-D-ketose 5-phosphate reductoisomerase (DXR). DXR-IN-1 is highly selective for P. falciparum DXR (IC50=0.030 μM). DXR-IN-1 inhibits the growth of P. falciparum by binding to the active site of DXR and blocking its catalytic activity .
    DXR-IN-1
  • HY-P10422
    Multi-Leu peptide

    ML-peptide, Multi-Leucine (ML)-peptide

    		 Autophagy Cancer
    Multi-Leu peptide (ML-peptide) is a potent inhibitor of PACE4 (Ki=22 nM). Multi-Leu peptide can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide can be used to study the specific mechanism of PACE4 in the development of prostate cancer .
    Multi-Leu peptide
  • HY-E70016
    Terminal deoxyribonucleotidyltransferase

    TdT

    		 DNA/RNA Synthesis Others Cancer
    Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells .
    Terminal deoxyribonucleotidyltransferase
  • HY-132913
    Cyclopropenone probe 1

    		Biochemical Assay Reagents Cancer
    Cyclopropenone probe 1 can specifically and efficiently modify a triple-negative breast cancer driver, glutathione S-transferase pi-1 (GSTP1), by covalently binding at the catalytic active site. Cyclopropenone probe 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Cyclopropenone probe 1
  • HY-P10422A
    Multi-Leu peptide triacetate

    ML-peptide, Multi-Leucine (ML)-peptide triacetate

    		 Autophagy Cancer
    Multi-Leu peptide (ML-peptide) triacetate is a potent inhibitor of PACE4 (Ki=22 nM). Multi-Leu peptide triacetate can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide triacetate can be used to study the specific mechanism of PACE4 in the development of prostate cancer .
    Multi-Leu peptide triacetate
  • HY-124308
    PS315

    		PKC Cancer
    PS315, a derivative of PS48 (HY-15967), is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing a displacement of the active site residue Lys111. PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity .
    PS315
  • HY-E70760
    NPM1 ALK Recombinant Human Active Protein Kinase

    		Anaplastic lymphoma kinase (ALK) Cancer
    The NPM1-ALK protein contains the NPM1 oligomerization motif and the ALK catalytic domain, is constitutively activated through autophosphorylation, and mediates malignant cell transformation by activating downstream effectors including STAT3. NPM1 ALK Recombinant Human Active Protein Kinase is a recombinant NPM1 ALK protein that can be used to study NPM1 ALK-related functions .
    NPM1 ALK Recombinant Human Active Protein Kinase
  • HY-162488
    Laccase-IN-3

    		Fungal Infection
    Laccase-IN-3 (Compound 2b) is a laccase inhibitor (IC50 = 1.02= μM) with significant antifungal activity. Laccase-IN-3 shows superior inhibitory effect on Botryosphaeria dothidea (EC50 = 0.17 mg/L). Laccase-IN-3 effectively blocks the catalytic function of laccase by binding to its active center. Laccase-IN-3 also disrupts pathogen cell membrane integrity and increases ROS .
    Laccase-IN-3
  • HY-175031
    GRL-07524

    		HIV Protease Infection
    GRL-07524 (Compound 4e) is a potent inhibitor of HIV-1 protease (Ki = 0.22 nM). GRL-07524 contains oxaspirocyclic carbamates as the P2 ligands. GRL-07524 exhibits good antiviral activity with an EC50 = 210 nM. GRL-07524 binds to the HIV-1 PR active site in one of the four symmetry independent molecules along with key catalytic residues .
    GRL-07524
  • HY-11107
    PHA-665752
    Maximum Cited Publications
    14 Publications Verification

    		 c-Met/HGFR Autophagy Apoptosis Cancer
    PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of c-Met kinase (Ki=4 nM; IC50=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases. PHA-665752 induces apoptosis and cell cycle arrest, and exhibits cytoreductive antitumor activity .
    PHA-665752
  • HY-167920
    Glutathione sulfonate

    S-Sulfoglutathione

    		 Endogenous Metabolite Cancer
    Glutathione sulfonate (S-Sulfoglutathione) is a multifunctional bioactive compound that inhibits angiogenesis and tumor growth. Glutathione sulfonate is a competitive inhibitor of glutathione S-transferase and is involved in the detoxification process and the binding of a variety of exogenous and endogenous compounds. Glutathione sulfonate acts in the substrate binding site of Escherichia coli glutathione S-transferase, affecting the catalytic mechanism. The structural characteristics of Glutathione sulfonate contribute to its inhibitory effect by hydrogen bonding in the active center of the enzyme .
    Glutathione sulfonate
  • HY-24312
    AD-mix-α

    		Biochemical Assay Reagents Others
    AD-mix-α is a mixture of organic compounds, commonly used to distinguish and identify asymmetric carbon atoms in chiral compounds. It consists of compounds containing catalytically active metals and chiral ligands. AD-mix-α is widely used in various organic synthesis reactions, such as hydrogenation, addition, and carbonylation reactions, to increase yield and reduce the formation of side reaction products. Although it has no direct application in the medical field, it plays an important role in the pharmaceutical industry and chemical research.
    AD-mix-α
  • HY-E70761
    NPM1 ALK F1174L Recombinant Human Active Protein Kinase

    		Anaplastic lymphoma kinase (ALK) Cancer
    The NPM1-ALK protein contains the NPM1 oligomerization motif and the ALK catalytic domain, is constitutively activated through autophosphorylation, and mediates malignant cell transformation by activating downstream effectors including STAT3. NPM1 ALK F1174L Recombinant Human Active Protein Kinase is a recombinant NPM1 ALK F1174L protein that can be used to study NPM1 ALK F1174L-related functions .
    NPM1 ALK F1174L Recombinant Human Active Protein Kinase
  • HY-W033831
    Rhodium(II) triphenylacetate dimer

    Rh2(TPA)4

    		 Endogenous Metabolite Biochemical Assay Reagents
    Rhodium(II) triphenylacetate dimer (Rh2(TPA)4) is an important catalyst with high C–H activation reaction activity. Rhodium(II) triphenylacetate dimer is widely used in organic synthesis to achieve the construction of complex molecules. Rhodium(II) triphenylacetate dimer can also be used to catalyze the synthesis of certain biologically active molecules and improve the preparation efficiency of compounds. Rhodium(II) triphenylacetate dimer exhibits excellent selectivity and reaction rate in catalytic reactions.
    Rhodium(II) triphenylacetate dimer
  • HY-E70691
    CLK1 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CLK1 is one of the dual specificity kinases and is the founding member of the 'LAMMER' family of kinases. CLK1 activity is positively regulated by phosphorylation on either tyrosine residues or serine/threonine residues, and is negatively regulated by steric constraints mediated by the N-terminal domain, as well as, by phosphorylation on a subset of serine/threonine residues within the catalytic domain. CLK1 Recombinant Human Active Protein Kinase is a recombinant CLK1 protein that can be used to study CLK1-related functions .
    CLK1 Recombinant Human Active Protein Kinase
  • HY-164144
    EPZ033294

    		Histone Methyltransferase Cancer
    EPZ033294 is an inhibitor of SYMD2 (IC50 is 3.9 nM). SYMD2 itself has catalytic activity and can methylate the lysine residue of BTF3 to BTF3me1, which was experimentally demonstrated by detecting an IC50 of 2.9 nM for inhibition of BTF3ME1 by SYMD2, indicating an active inhibition of SYMD2 by EPZ033294. EPZ033294 (0-50 µM) has an inhibitory effect on SYMD2 and a concentration-dependent inhibitory effect in 293T .
    EPZ033294
  • HY-E70704
    EGFR G719C Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719C Recombinant Human Active Protein Kinase is a recombinant EGFR G719C protein that can be used to study EGFR G719C-related functions .
    EGFR G719C Recombinant Human Active Protein Kinase
  • HY-E70706
    EGFR L718Q Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L718Q Recombinant Human Active Protein Kinase is a recombinant EGFR L718Q protein that can be used to study EGFR L718Q-related functions .
    EGFR L718Q Recombinant Human Active Protein Kinase
  • HY-E70695
    EGFR C797S Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR C797S Recombinant Human Active Protein Kinase is a recombinant EGFR C797S protein that can be used to study EGFR C797S-related functions .
    EGFR C797S Recombinant Human Active Protein Kinase
  • HY-E70707
    EGFR L858R Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L858R Recombinant Human Active Protein Kinase is a recombinant EGFR L858R protein that can be used to study EGFR L858R-related functions .
    EGFR L858R Recombinant Human Active Protein Kinase
  • HY-W054259
    BFMO

    N,N'-Difurfuryloxamide; N1,N2-Bis(furan-2-ylmethyl)oxalamide

    		 Biochemical Assay Reagents Others
    BFMO is a bidentate ligand for copper (Cu) catalysts that can effectively promote copper-catalyzed N-arylation coupling reactions of (hetero)aryl bromides with aniline, cyclic secondary amines, and acyclic secondary amines. BFMO coordinates with copper ions to form stable catalytically active species, which reduces the activation energy of the reaction and improves the reactivity of the substrate. It exhibits excellent selectivity for coupling of acyclic secondary amines with large steric hindrance, and can achieve direct monoarylation of piperazine with (hetero)aryl bromides to generate important pharmaceutical structural units .
    BFMO
  • HY-E70708
    EGFR L861Q Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L861Q Recombinant Human Active Protein Kinase is a recombinant EGFR L861Q protein that can be used to study EGFR L861Q-related functions .
    EGFR L861Q Recombinant Human Active Protein Kinase
  • HY-E70705
    EGFR G719S Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719S Recombinant Human Active Protein Kinase is a recombinant EGFR G719S protein that can be used to study EGFR G719S-related functions .
    EGFR G719S Recombinant Human Active Protein Kinase
  • HY-E70709
    EGFR T790M Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR T790M Recombinant Human Active Protein Kinase is a recombinant EEGFR T790M protein that can be used to study EGFR T790M-related functions .
    EGFR T790M Recombinant Human Active Protein Kinase
  • HY-173267
    CES2A-IN-2

    		Carboxylesterase (CES) Metabolic Disease Cancer
    CES2A-IN-2 (compound 14n) is an orally active, highly specific, irreversible and covalent CES2A inhibitor with an IC50 of 0.04 nM for human CES2A. CES2A-IN-2 covalently binds to CES2A by specifically targeting the catalytic serine residue (Ser-228). CES2A-IN-2 can significantly ameliorate Irinotecan-triggered gut toxicity (ITGT) without diminishing the anti-tumor effects of Irinotecan (HY-16562) in tumor-bearing mice .
    CES2A-IN-2
  • HY-E70703
    EGFR d752-759 Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d752-759 Recombinant Human Active Protein Kinase is a recombinant EGFR d752-759 protein that can be used to study EGFR d752-759-related functions .
    EGFR d752-759 Recombinant Human Active Protein Kinase
  • HY-E70697
    EGFR d746-750 Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750 Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750 protein that can be used to study EGFR d746-750-related functions .
    EGFR d746-750 Recombinant Human Active Protein Kinase
  • HY-110196
    (S)-PFI-2 hydrochloride

    		Histone Methyltransferase Others
    (S)-PFI-2 hydrochloride is an inhibitor of lysine methyltransferase SETD7 and is approximately 500-fold more active than its enantiomer (R)-PFI-2. (R)-PFI-2 is a cofactor-dependent and substrate-competitive inhibitor. (R)-PFI-2 can occupy the substrate peptide binding groove of SETD7 (including the catalytic lysine binding channel) and interact with the cofactor The donor methyl group is in direct contact. However, (S)-PFI-2 was not observed to have the same interaction as (R)-PFI-2 .
    (S)-PFI-2 hydrochloride
  • HY-E70711
    EGFR T790M/L858R Recombinant Human Active Protein Kinase

    		EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR T790M/L858R Recombinant Human Active Protein Kinase is a recombinant EGFR T790M/L858R protein that can be used to study EGFR T790M/L858R-related functions .
    EGFR T790M/L858R Recombinant Human Active Protein Kinase
  • HY-16138
    Ivaltinostat

    CG-200745

    		 HDAC MDM-2/p53 Apoptosis Cancer
    Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects .
    Ivaltinostat

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: